Starbucks Corp now has $84.53B valuation. In the current trading session, the stock has seen a change of -4.80% recently hitting $15.88. The volume of 0.67 Million shares climbed down over an trading activity of 412.43 Million shares.
Shares of Corcept Therapeutics (NASDAQ:CORT) now have an Average Brokerage Recommendation of 1.75, number of Recs in ABR is 4 while industry rank of the company by ABR is out of 265. It has underperformed by 4.22% the S&P500. Evanson Asset Ltd Liability Corp has invested 0.11% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. About 938,744 shares traded.
Taking a broader look at the analyst consensus, according to 5 analysts Corcept Therapeutics (NASDAQ:CORT)'s price will reach at $17.8 during 52 weeks. It was reported on Dec, 5 by Barchart.com.
Investors sentiment increased to 2.43 in 2017 Q2. Its up 1.35, from 1.08 in 2017Q1. It increased, as 11 investors sold Corcept Therapeutics Incorporated shares while 29 reduced holdings. That's a potential 24.4 increase relative to where Corcept Therapeutics Incorporated (NASDAQ:CORT) has been trading recently. Fincl Bank Of New York Mellon Corp stated it has 926,350 shares. Barometer Cap Mgmt, Ontario - Canada-based fund reported 229,400 shares. Los Angeles Capital Management & Equity Research Inc. owned approximately 0.06% of Corcept Therapeutics worth $1,352,000 at the end of the most recent quarter. Manufacturers Life Ins The accumulated 181,414 shares. Wells Fargo & Company Mn reported 96,081 shares.
Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Whitnell And Communications owns 17,900 shares for 0.35% of their portfolio. Vanguard Gru invested in 4.44M shares. Secor Cap Advisors Lp has 36,689 shares. Millennium Management Lc owns 652,162 shares. Sg Americas Securities Ltd Llc holds 0% or 9,255 shares.
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of 103.76 and a beta of 1.72. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 14.26 P/E ratio. For the past 5 years, the company's revenue has grown 0%, while the company's earnings per share has grown 16.9%. CORT's profit will be $21.69M for 21.95 P/E if the $0.19 EPS becomes a reality. During the same period in the prior year, the company earned $0.02 EPS. equities research analysts expect that Corcept Therapeutics Incorporated will post 0.47 EPS for the current fiscal year.
Ratings analysis reveals 100% of Corcept Therapeutics's analysts are positive. Therefore 100% are positive. Corcept Therapeutics Incorporated has a fifty-two week low of $6.70 and a fifty-two week high of $20.77. Corcept Therapeutics had 7 analyst reports since February 2, 2017 according to SRatingsIntel. The stock has "Buy" rating by Stifel Nicolaus on Friday, November 3. Corcept Therapeutics presently has a consensus rating of "Buy" and an average target price of $18.20.
Since June 14, 2017, it had 0 insider buys, and 1 insider sale for $606,300 activity. 104 funds opened positions while 473 raised stakes. The funds in our partner's database now have: 67.64 million shares, up from 60.14 million shares in 2017Q1. Tfs Capital Limited Liability holds 10,692 shares. Cs Mckee Lp holds 273,780 shares.
Shares of Corcept Therapeutics (CORT) remained flat at $$16.68 on Tuesday. Gibraltar Industries, Inc. (ROCK) has risen 13.48% since December 4, 2016 and is uptrending. Convergence Inv Prns Limited Liability, a Wisconsin-based fund reported 111,231 shares. 121,246 were reported by Stephens Ar. Prudential reported 633,223 shares or 0.01% of all its holdings. Out of 4 Wall Street analysts rating Corcept Therapeutics, 4 give it "Buy", 0 "Sell" rating, while 0 recommend "Hold". As per Thursday, September 28, the company rating was maintained by Keefe Bruyette & Woods. KeyBanc Capital Markets maintained the shares of BABA in report on Friday, August 18 with "Overweight" rating. There are brokerage firms with lower targets than the average, including one setting a price target of $6. Earnings surprises can have a huge impact on a company's stock price. The company was initiated on Tuesday, April 5 by Evercore. On Wednesday, August 12 the stock rating was maintained by Nomura with "Buy". The firm earned "Buy" rating on Thursday, January 21 by Standpoint Research.